Le Lézard
Classified in: Business
Subjects: OTC, ATY

AXOGEN EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against AxoGen, Inc. -- AXGN


NEW YORK, March 2, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of AxoGen, Inc. (NASDAQ: AXGN): (1) pursuant and/or traceable to the false and/or misleading registration statement and prospectus issued in connection with AxoGen's November 2017 secondary public offering; and/or (2) purchased or otherwise acquired AxoGen securities pursuant and/or traceable to AxoGen's false and/or misleading registration statement and prospectus issued in connection with AxoGen's May 2018 secondary public offering; and/or (3) purchased or otherwise acquired AxoGen securities between August 7, 2017 and December 18, 2018, inclusive (the "Class Period"). The lawsuit seeks to recover damages for AxoGen investors under the federal securities laws.

Rosen Law Firm, P.A. Logo

To join the AxoGen class action, go to https://www.rosenlegal.com/cases-1478.html or call Phillip Kim, Esq. or Zachary Halper, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR'S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) AxoGen aggressively increased prices to mask lower sales; (2) AxoGen's pricing alienated customers and AxoGen's future growth; (3) ambulatory surgery centers form a significant part of the market for AxoGen's products; (4) such centers were especially sensitive to price increases; (5) AxoGen was dependent on a small number of surgeons whom AxoGen paid to generate sales; (6) AxoGen's consignment model for inventory was reasonably likely to lead to channel stuffing; (7) AxoGen offered purchase incentives to sales representatives to encourage channel stuffing; (8) AxoGen's sales representatives were encouraged to backdate revenue to artificially inflate metrics; (9) AxoGen lacked adequate internal controls to prevent such channel stuffing and backdating of revenue; (10) AxoGen's key operating metrics, such as number of active accounts, were overstated; and (11) as a result of the foregoing, defendants' positive statements about AxoGen's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 11, 2019. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to https://www.rosenlegal.com/cases-1478.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Zachary Halper, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013.

-------------------------------

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      Zachary Halper, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 34th Floor
      New York, NY  10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      [email protected]
      [email protected]
      www.rosenlegal.com

SOURCE Rosen Law Firm, P.A.


These press releases may also interest you

at 12:15
According to a "highly troubling" new study, the rising number of cancer cases in young people is being attributed to "accelerated aging." Further alarm is being spread by the United Nations, whose health authorities are predicting global cancer...

at 12:12
One of the biggest pressures on people right now is housing. Young Canadians ? particularly Millennials and Gen Z ? are being priced out of their communities. Families are finding it difficult to get a good place to settle down. Rising rents and the...

at 12:11
The following issues have been halted by CIRO: Company: STLLR Gold Inc. TSX Symbol: STLR.WT All Issues: No Reason: Pending Delisting Halt Time (ET): 12:00 PM CIRO can make a decision to impose a temporary suspension (halt) of trading in a security...

at 11:54
Magdalena Furman, a PhD student in Physics at the University of Warsaw, Poland, has been selected as the recipient of the APL Photonics 2023 Future Luminary Award for her work in advancing the understanding of optical bistability and optical limiting...

at 11:45
Connect First and Servus Credit Union announced, today, that Perry Dooley has become the inaugural Chair of the Board of Directors for the newly merged entity. This follows the credit union's first post-merger Board meeting at which Dooley was...

at 11:45
POET Technologies Inc. ("POET" or the "Company") , the designer and developer of the POET Optical Interposertm, Photonic Integrated Circuits (PICs) and light sources for the data center, tele-communication and AI markets, today announced the closing...



News published on and distributed by: